We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AstraZeneca announced Tuesday an agreement to sell US rights to Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) for a total upfront consideration of $1.5 billion, including $1 billion in cash. Under the deal for the respiratory syncytial virus (R